I last reviewed Abbvie (ABBV) in my November 12, 2022 post at which time I expressed my relief that ABBV was deleveraging. Now, however, ABBV's debt will increase because of its recently announced ImmunoGen (IMGN) acquisition. I am, therefore, not increasing my Abbvie exposure for reasons presented herein. In my previous post, I also commented [...]